The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells
1998

Liarozole-fumarate Enhances Antiproliferative Activity of Retinoic Acid in Breast Cancer Cells

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): J Van heusden, W Wouters, FCS Ramaekers, MDWG Krekels, L Dillen, M Borgers, G Smets

Primary Institution: University of Maastricht; Janssen Research Foundation

Hypothesis

Does liarozole-fumarate enhance the antiproliferative activity of all-trans-retinoic acid (ATRA) and its catabolites in MCF-7 human breast cancer cells?

Conclusion

Liarozole-fumarate enhances the antiproliferative activity of ATRA and its catabolites but not of its stereoisomers in MCF-7 cells.

Supporting Evidence

  • Liarozole-fumarate significantly enhanced the antiproliferative activity of ATRA and its catabolites.
  • Liarozole-fumarate did not enhance the activity of ATRA stereoisomers.
  • MCF-7 cells showed a BrdU labelling index of 25.2 ± 1.4% under control conditions.
  • Statistical analysis showed significant differences at p<0.01.

Takeaway

Liarozole-fumarate helps a cancer treatment work better by stopping the body from breaking down a medicine called retinoic acid too quickly.

Methodology

MCF-7 cells were treated with liarozole-fumarate and various concentrations of ATRA and its catabolites, and cell proliferation was measured using BrdU incorporation.

Limitations

The study primarily focuses on MCF-7 cells, which may not represent all breast cancer types.

Participant Demographics

MCF-7 human breast cancer cells were used in the study.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication